NASDAQ:ASND

Ascendis Pharma A/S Stock Forecast, Price & News

$161.51
+2.29 (+1.44 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$158.20
$163.21
50-Day Range
$112.67
$176.92
52-Week Range
$109.36
$183.98
Volume298,213 shs
Average Volume222,059 shs
Market Capitalization$9.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.8
30 days | 90 days | 365 days | Advanced Chart
Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.


Ascendis Pharma A/S logo

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.08 out of 5 stars

Medical Sector

468th out of 1,349 stocks

Pharmaceutical Preparations Industry

229th out of 663 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

Is Ascendis Pharma A/S a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ascendis Pharma A/S stock.
View analyst ratings for Ascendis Pharma A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Ascendis Pharma A/S?

Wall Street analysts have given Ascendis Pharma A/S a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ascendis Pharma A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for Ascendis Pharma A/S
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings data on Tuesday, August, 24th. The biotechnology company reported ($2.50) earnings per share for the quarter, topping analysts' consensus estimates of ($2.75) by $0.25. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 56.44% and a negative net margin of 9,108.77%.
View Ascendis Pharma A/S's earnings history
.

How has Ascendis Pharma A/S's stock been impacted by Coronavirus?

Ascendis Pharma A/S's stock was trading at $118.53 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ASND shares have increased by 36.3% and is now trading at $161.51.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ASND?

10 brokerages have issued 12 month target prices for Ascendis Pharma A/S's stock. Their forecasts range from $175.00 to $216.00. On average, they anticipate Ascendis Pharma A/S's share price to reach $191.88 in the next year. This suggests a possible upside of 18.8% from the stock's current price.
View analysts' price targets for Ascendis Pharma A/S
or view top-rated stocks among Wall Street analysts.

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the following people:
  • Jan Møller Mikkelsen, President, CEO & Executive Director
  • Scott Thomas Smith, Chief Financial Officer & Senior Vice President
  • Kennett Sprogøe, Senior Vice President, Head-Innovation & Research
  • Mark A. Bach, Senior Vice President-Clinical Development
  • Lotte Sønderbjerg, Chief Administrative Officer & Senior VP

Who are some of Ascendis Pharma A/S's key competitors?

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (12.64%), Artisan Partners Limited Partnership (11.94%), FMR LLC (10.00%), Price T Rowe Associates Inc. MD (9.40%), Westfield Capital Management Co. LP (3.75%) and Avoro Capital Advisors LLC (3.53%).

Which institutional investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., BlackRock Inc., TimesSquare Capital Management LLC, California Public Employees Retirement System, JPMorgan Chase & Co., Ensign Peak Advisors Inc, Baillie Gifford & Co., and Berylson Capital Partners LLC.

Which institutional investors are buying Ascendis Pharma A/S stock?

ASND stock was bought by a variety of institutional investors in the last quarter, including Avoro Capital Advisors LLC, Invesco Ltd., RA Capital Management L.P., Artisan Partners Limited Partnership, Putnam Investments LLC, CIBC Asset Management Inc, Westfield Capital Management Co. LP, and Alliancebernstein L.P..

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $161.51.

How much money does Ascendis Pharma A/S make?

Ascendis Pharma A/S has a market capitalization of $9.11 billion and generates $7.94 million in revenue each year. The biotechnology company earns $-478,570,000.00 in net income (profit) each year or ($9.46) on an earnings per share basis.

How many employees does Ascendis Pharma A/S have?

Ascendis Pharma A/S employs 482 workers across the globe.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is www.ascendispharma.com.

Where are Ascendis Pharma A/S's headquarters?

Ascendis Pharma A/S is headquartered at TUBORG BOULEVARD 12, HELLERUP G7, DK-2900.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at (457) 022-2244 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.